Journal
LUNG CANCER
Volume 70, Issue 1, Pages 103-109Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2010.01.011
Keywords
Lipocalin; Cancer; Lung; Prostaglandin D-2; A549; Adenocarcinoma
Categories
Funding
- Winthrop-University Hospital
Ask authors/readers for more resources
Previously, we demonstrated that lipocalin-type prostaglandin D-2 synthase (L-PGDS) induces apoptosis and prevents cell cycle progression in several cell types. In this study we determined the expression of L-PGDS in a variety of human lung tumor types. While L-PGDS expression was evident in the surrounding margins, we observed significantly decreased protein and gene expression in the tumor tissue. Using RTPCR we demonstrated that L-PGDS gene expression decreased proportionately with tumor progression. In addition, we demonstrated that exogenously added L-PGDS could suppress the hyperproliferation and PDGF-stimulated migration of A549 cells, a cultured carcinomic human alveolar basal epithelial cell line. We conclude that L-PGDS may play a key role in modulating lung cancer growth and may offer a novel diagnostic and therapeutic approach for treatment. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available